Global

Neurology Is Trying to Stop Nerves Dying, Not Just Treat What Is Left

Cardiac rehab saves lives. Health systems still treat it like optional aftercare

BMI is not enough. Cardiometabolic risk is hiding in where fat lives

Resistant hypertension may need a diagnostic revolution, not just another drug

When diabetes tech fails, personalised care fails with it

AI genomics market set to hit $9.3B by 2030, but regulation and equity gaps remain unresolved

Heart pumps save lives. FDA’s latest Impella alerts show why cardiac device safety cannot stop at approval.
Type 1 diabetes has a kidney problem. FDA is now fast-tracking a possible answer.

The Biomarker Test Cannot Wait Until Relapse
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
